07 May 2021 : Clinical Research
Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis
Anthony Matta123ABCDEF*, Vanina Bongard12ABCDEF, Frédéric Bouisset12ABCDEF, Dorota Taraszkiewicz12ABCDEF, Jean-Pierre Rabès4BDEF, Jean Ferrières12ABCDEFGDOI: 10.12659/MSM.928784
Med Sci Monit 2021; 27:e928784
Table 3 A comparison of the responder rate between the 3 groups.
| Whole population (n=123) | PCSK9i (n=83) | PCSK9i+ezetimibe (n=12) | PCSK9i+statin and ezetimibe (n=28) | |
|---|---|---|---|---|
| Responders, n (%) | 61 (49.6%) | 32 (38.6%) | 7 (58.3%) | 22 (78.6%) |
| Odds ratio | 2.20 | 6 | ||
| 95% Confidence interval | (0.6–8.1) | (2–17.6) | ||
| P value | 0.24 | 0.001 | ||
| PCSK9i – proprotein convertase subtilisin/kexin type 9 inhibitors. | ||||